JP2008505157A5 - - Google Patents

Download PDF

Info

Publication number
JP2008505157A5
JP2008505157A5 JP2007519725A JP2007519725A JP2008505157A5 JP 2008505157 A5 JP2008505157 A5 JP 2008505157A5 JP 2007519725 A JP2007519725 A JP 2007519725A JP 2007519725 A JP2007519725 A JP 2007519725A JP 2008505157 A5 JP2008505157 A5 JP 2008505157A5
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
optionally
alkyl
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007519725A
Other languages
English (en)
Japanese (ja)
Other versions
JP5142713B2 (ja
JP2008505157A (ja
Filing date
Publication date
Priority claimed from DE102004033670A external-priority patent/DE102004033670A1/de
Application filed filed Critical
Publication of JP2008505157A publication Critical patent/JP2008505157A/ja
Publication of JP2008505157A5 publication Critical patent/JP2008505157A5/ja
Application granted granted Critical
Publication of JP5142713B2 publication Critical patent/JP5142713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2007519725A 2004-07-09 2005-07-07 新規ピリドジヒドロピラジノン、その製造方法及びその薬物としての使用 Active JP5142713B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004033670A DE102004033670A1 (de) 2004-07-09 2004-07-09 Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
DE102004033670.9 2004-07-09
PCT/EP2005/007347 WO2006005510A1 (de) 2004-07-09 2005-07-07 Neue pyridodihydropyrazinone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
JP2008505157A JP2008505157A (ja) 2008-02-21
JP2008505157A5 true JP2008505157A5 (US07794700-20100914-C00125.png) 2008-09-04
JP5142713B2 JP5142713B2 (ja) 2013-02-13

Family

ID=35033446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519725A Active JP5142713B2 (ja) 2004-07-09 2005-07-07 新規ピリドジヒドロピラジノン、その製造方法及びその薬物としての使用

Country Status (6)

Country Link
US (2) US7625899B2 (US07794700-20100914-C00125.png)
EP (1) EP1768981B1 (US07794700-20100914-C00125.png)
JP (1) JP5142713B2 (US07794700-20100914-C00125.png)
CA (1) CA2573092C (US07794700-20100914-C00125.png)
DE (1) DE102004033670A1 (US07794700-20100914-C00125.png)
WO (1) WO2006005510A1 (US07794700-20100914-C00125.png)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP2013208B1 (en) * 2006-04-21 2011-06-22 Pfizer Products Inc. Pyridin[3,4-b]pyrazinones
ES2631003T3 (es) 2006-10-19 2017-08-25 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
EP2185559A1 (en) * 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2190849B1 (en) * 2007-08-15 2013-11-20 Vertex Pharmceuticals Incorporated 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
WO2009105509A1 (en) * 2008-02-21 2009-08-27 Boehringer Ingelheim International Gmbh Amine and ether compounds which modulate the cb2 receptor
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
US20120329803A1 (en) * 2010-02-17 2012-12-27 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CA2895426A1 (en) * 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydroquinoxalinones
JP2016525135A (ja) * 2013-07-23 2016-08-22 バイエル ファーマ アクチエンゲゼルシャフト BETタンパク質およびポロ様キナーゼの二重阻害薬としての置換されたジヒドロピリド[3,4−b]ピラジノン類
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
WO2015193229A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
WO2015193228A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
WO2016032202A2 (ko) * 2014-08-26 2016-03-03 엘지전자 주식회사 무선 통신 시스템에서 동기 신호를 송수신하는 방법 및 이를 수행하는 장치
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8303657A (nl) 1983-10-24 1985-05-17 Pharmachemie Bv Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan.
DE3537761A1 (de) 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
DE68908786T2 (de) 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
FR2645152B1 (fr) 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
US5043270A (en) * 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
CA2029651C (en) 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (US07794700-20100914-C00125.png) 1992-09-26 1996-04-21 Hoechst Ag
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
CO4410191A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
KR100400419B1 (ko) 1995-05-19 2003-12-18 신젠타 파티서페이션즈 아게 방향족니트로화합물의촉매적수소화방법
US5698556A (en) 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
HU226167B1 (hu) 1996-09-23 2008-05-28 Lilly Co Eli Olanzapin-dihidrát D, elõállítása és az azt tartalmazó gyógyszerkészítmények
ATE229955T1 (de) 1998-08-11 2003-01-15 Pfizer Prod Inc Substituierte 1,8-naphthyridin-4(1h)-one als phosphodiesterase 4-inhibitoren
AU777468B2 (en) * 1999-09-15 2004-10-21 Warner-Lambert Company Pteridinones as kinase inhibitors
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
PL358271A1 (en) 2000-03-06 2004-08-09 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
DE10018783A1 (de) 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10058119A1 (de) 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
WO2002076954A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076985A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
HUP0401293A3 (en) 2001-09-04 2008-03-28 Boehringer Ingelheim Pharma Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
ES2293965T3 (es) 2001-12-14 2008-04-01 Laboratoires Serono Sa Metodo de inducir la ovulacion utilizando un modulador no polipeptidico de los niveles de camp.
PL372890A1 (en) 2002-05-03 2005-08-08 Schering Aktiengesellschaft Thiazolidinones and the use thereof as polo-like kinase inhibitors
CA2493908A1 (en) 2002-08-08 2004-02-19 Smithkline Beecham Corporation Thiophene compounds
EA008778B1 (ru) 2003-02-26 2007-08-31 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20070134200A1 (en) 2003-03-26 2007-06-14 Wyeth Immunogenic composition and methods
CA2522158C (en) 2003-04-14 2018-03-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
WO2005067935A1 (de) 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen
DE102004002557A1 (de) 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
DE102004034623A1 (de) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
EP1784406A1 (de) 2004-08-27 2007-05-16 Boehringer Ingelheim International GmbH Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
CA2617589A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP1994002A1 (en) * 2006-03-07 2008-11-26 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them
EP2185559A1 (en) * 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative

Similar Documents

Publication Publication Date Title
JP2008505157A5 (US07794700-20100914-C00125.png)
JP2020169171A5 (US07794700-20100914-C00125.png)
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
JP2008533191A5 (US07794700-20100914-C00125.png)
JP2009504763A5 (US07794700-20100914-C00125.png)
JP2009536660A5 (US07794700-20100914-C00125.png)
JP2017519781A5 (US07794700-20100914-C00125.png)
JP2006182786A5 (US07794700-20100914-C00125.png)
JP2005501904A5 (US07794700-20100914-C00125.png)
JP2008510770A5 (US07794700-20100914-C00125.png)
JP2004516314A5 (US07794700-20100914-C00125.png)
JP2003535843A5 (US07794700-20100914-C00125.png)
JP2008505117A5 (US07794700-20100914-C00125.png)
JP2013510120A5 (US07794700-20100914-C00125.png)
JP2017504576A5 (US07794700-20100914-C00125.png)
JP2006524662A5 (US07794700-20100914-C00125.png)
JP2007504171A5 (US07794700-20100914-C00125.png)
JP2014503574A5 (US07794700-20100914-C00125.png)
JP2014500296A5 (US07794700-20100914-C00125.png)
JP2005511699A5 (US07794700-20100914-C00125.png)
JP2005530811A5 (US07794700-20100914-C00125.png)
JP2019535723A5 (US07794700-20100914-C00125.png)
JP2015521156A5 (US07794700-20100914-C00125.png)
JP2019527724A5 (US07794700-20100914-C00125.png)
JP2021501756A5 (US07794700-20100914-C00125.png)